Advances in Cancer Immunotherapy™ - Philadelphia, PA

Friday, August 4, 2017, 8:00 AM - 2:00 PM ET

Organizers:
David H. Henry, MD – University of Pennsylvania
Ellen Napier, CRNP – University of Pennsylvania
Stephen J. Schuster, MD – University of Pennsylvania

Share This Event In Your Network

ACI Program Registration Cost Information

Program Purpose

Specifically designed by the Society for Immunotherapy of Cancer (SITC) for clinical oncologists, registered nurses, pharmacists, emergency physicians and the entire cancer care team, the Advances in Cancer Immunotherapy™ (ACI) programs are introductory, CME-, CPE- and CNE-certified programs. Presented by leading and local authorities in tumor immunology and cancer immunotherapy, these six-hour programs will facilitate understanding of:

  • The rationale for common approaches to immunotherapy
  • The clinical applications of immunotherapy for disease states with FDA-approved treatments (melanoma, and lung, genitourinary, hematologic, and head and neck cancers)
  • Operational and reimbursement barriers to implementing immunotherapy in a community setting and strategies to overcome them
  • The identification and management of immune-related adverse events from the nursing and prescriber perspective in the clinic and emergency settings

Attendees will also have an opportunity for connecting with regional experts in the immunotherapy field at the live event, through two Immuno-Oncology (IO) Cup o' Joe webinars after the program, and indefinitely through a dedicated online community forum. These connections will serve as ongoing resources while clinical oncologists and other healthcare providers incorporate immunotherapy into practice. Breakfast and lunch will be served at the live portion of this event.

For more information, including program objectives, click here.

This program is presented in collaboration with the American Academy of Emergency Medicine (AAEM) and the Association of Community Cancer Centers (ACCC).      

                    

 

 

Program Registration

Advance online registration for the Advances in Cancer Immunotherapy™ in Philadelphia, PA is NOW OPEN!

To take advantage of the discounted early registration rates listed here, register by July 14, 2017 at 5 p.m. ET.
Advance registration will close on July 28, 2017 at 5 p.m. ET, and on-site registration will be available as space permits.
You can find a PDF version of the registration form here.

SITC members are eligible for discounted registration rates. To receive discounted member rates, your membership dues must be current through 2017.

Click here to learn more about the registration rates for members and non-members for this program.

Program Agenda

Preprogram Course: Introduction to Immunology

Participation in this online preprogram course is strongly recommended as it contains information that will not be covered at the program on August 4. This interactive course provides foundational knowledge that is necessary for understanding cancer immunotherapy content that will be discussed at the in-person program. Please click HERE to access the course.


August 4 Program

5.5 AMA PRA Category 1 Credits™ Click here for more detailed CME, CNE and CPE information and program objectives.

Presentations include time for Audience Response System (ARS)-assisted audience
interaction as well as general question and answer time.

7 – 8 a.m.

Check-in, Onsite Registration and Networking

Part A: Introduction to Incorporating Immunotherapy Into Clinical Practice

Session I: From Basic Principles to Clinical Applications of Cancer Immunotherapy

8 – 8:05 a.m.

Welcome, Introduction, and Pretest Questions by the Society for Immunotherapy of Cancer

8:05 – 8:35 a.m.

Basic Principles of Cancer Immunotherapy
David H. Henry, MD – University of Pennsylvania

8:35 – 8:55 a.m.

Immunotherapy for the Treatment of Melanoma
Marlana Orloff, MD – Thomas Jefferson University Hospital

8:55 – 9:15 a.m.

Immunotherapy for the Treatment of Lung Cancer
Corey J. Langer, MD – University of Pennsylvania

9:15 – 9:35 a.m.

Immunotherapy for the Treatment of Genitourinary Cancers
Vivek Narayan, MD MSCE – University of Pennsylvania

9:35 – 9:55 a.m

Immunotherapy for the Treatment of Hematologic Malignancies
Stephen J. Schuster, MD – University of Pennsylvania

9:55 – 10:15 a.m

Immunotherapy for the Treatment of Head and Neck Cancers
Joshua Bauml, MD – University of Pennsylvania

10:15 – 10:25 a.m

 Break

Session II: Overcoming Barriers to Incorporating Immunotherapy Into Community Practice

10:25 – 10:30 a.m.

Information About the Society for Immunotherapy of Cancer Resources

10:30 – 11 a.m.

Effective Practices for Incorporating Immunotherapy Into Hospital Operations
Matthew Zibelman, MD – Fox Chase Cancer Center

11 – 11:30 a.m.

Coverage and Reimbursement Challenges and Strategies
Matthew Zibelman, MD – Fox Chase Cancer Center

11:30 – 11:35 a.m.

Take-Home Points for Part A

11:35 a.m. – noon

Lunch

Part B: Immune-Related Adverse Event (irAE) Management

noon – 12:20 p.m.

Mechanisms of Immune-Related Adverse Events
Justine V. Cohen, DO – Massachusetts General Hospital

12:20 – 12:50 p.m.

Nursing Perspective on irAEs: Patient Education, Monitoring and Management
Ellen Napier, CRNP – University of Pennsylvania

12:50 – 1:20 p.m.

Management and Mitigation of irAEs for Immunotherapy Prescribers
Kathleen Madden, MSN, FNP-BC, AOCNP, APHN – New York University Cancer Institute

1:20 – 1:50 p.m.

Identification and Management of Immune-Related Adverse Events in the Emergency Setting
Maura Sammon, MD, FAAEM – Temple University School of Medicine

1:50 – 1:55 p.m.

Posttest Questions by the Society for Immunotherapy of Cancer

1:55 – 2 p.m.

Take-Home Points for Part B and Closing Remarks


The 2017 Advances in Cancer Immunotherapy™ series is supported in part by independent medical educational grants
from Aduro Biotech, Inc., Amgen, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Merck & Co., Inc. and Prometheus Laboratories Inc.

Location

Courtyard Philadelphia City Avenue
4100 Presidential Boulevard
Philadelphia, PA 19131

Tags

  • CE
  • CME
  • CNE
  • CPE
  • Disease
  • Genitourinary Cancer
  • Head and Neck Cancer
  • Hematologic Malignancies
  • Lung Cancer
  • Prostate Cancer
  • Skin Cancer
  • Level
  • Introductory
  • Modality
  • In person Event
  • SITC Scientific Projects
  • Cancer Immunotherapy Guidelines
  • Source
  • Advances in Cancer Immunotherapy ACI
  • Therapies
  • Adverse Events
  • Cytokines
  • Immune Checkpoint Inhibitors
  • Toxicities
  • User Type
  • Allied Health
  • Clinician
  • Nurse
  • Oncologist
  • Patient
  • Patient Advocate
  • Pharmacist
  • Primary Care Physician
  • Year
  • 2017